{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Finger RP"],"funding":["Bayer"],"pubmed_abstract":["<h4>Background</h4>Systematically review the evidence describing the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on neovascular age-related macular degeneration (nAMD) patient outcomes and healthcare resource utilization.<h4>Methods</h4>A systematic literature review was completed using Medline and EMBASE for publications prior to July 2018, and proceedings from major ophthalmology conferences (January 2016 to July 2018). The search strategy combined terms for nAMD with terms for anti-VEGF and study design. The review focused on publications describing the impact of anti-VEGF on blindness, visual impairment, vision-related quality of life (VRQoL), mortality, and costs. The search targeted data collected in epidemiological or observational studies to reflect real-w"],"journal":["BMC ophthalmology"],"pagination":["294"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7368708"],"repository":["biostudies-literature"],"pubmed_title":["Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems."],"pmcid":["PMC7368708"],"pubmed_authors":["Finger RP","Talks JS","Wong TY","Korobelnik JF","Pantiri K","Carrasco J","Mitchell P","Daien V","Eldem BM","Sakamoto T"],"additional_accession":[]},"is_claimable":false,"name":"Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.","description":"<h4>Background</h4>Systematically review the evidence describing the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on neovascular age-related macular degeneration (nAMD) patient outcomes and healthcare resource utilization.<h4>Methods</h4>A systematic literature review was completed using Medline and EMBASE for publications prior to July 2018, and proceedings from major ophthalmology conferences (January 2016 to July 2018). The search strategy combined terms for nAMD with terms for anti-VEGF and study design. The review focused on publications describing the impact of anti-VEGF on blindness, visual impairment, vision-related quality of life (VRQoL), mortality, and costs. The search targeted data collected in epidemiological or observational studies to reflect real-w","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-26T08:15:34.643Z","creation":"2020-10-01T07:04:53Z"},"accession":"S-EPMC7368708","cross_references":{"pubmed":["32680477"],"doi":["10.1186/s12886-020-01554-2"]}}